You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九典制药(300705.SZ):盐酸左西替利嗪片拟中标第二批全国药品集中采购
格隆汇 01-17 19:59

格隆汇1月17日丨九典制药(300705.SZ)公布,2020年1月17日,公司已通过国家药品监督管理局仿制药质量和疗效一致性评价的盐酸左西替利嗪片参加了全国药品集中采购并拟中标,拟中标产品基本情况如下:

药品名称:盐酸左西替利嗪片;规格:5mg;包装数量:24片;适应症:治疗下述疾病的过敏相关的症状:过敏性鼻炎(包括季节性持续过敏性鼻炎和常年性持续性过敏性鼻炎)及慢性特发性荨麻疹。拟中标价格:1.38元

此次拟中标的品种如确认中标,医疗机构应优先使用此次药品集中采购中选药品,并确保完成约定采购量。后续签订购销合同并实施后,将提升公司品牌影响力,对公司长远发展产生积极影响。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account